Antiretroviral News and Research

RSS

Study: High levels of depressive symptoms may be associated with delayed ART initiation

Researchers from Boston University's School of Medicine and College of Arts and Sciences found that among HIV-infected Russian drinkers, depressive symptom severity alone was not significantly associated with lower rates of antiretroviral therapy initiation. However, when examining cognitive symptoms of depression, results showed that high levels of depressive symptoms may be associated with delayed ART initiation.

22 Dec 2013

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.

18 Dec 2013

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg.

17 Dec 2013

HIV self-test screening strategy: an interview with Dr. Nitika Pant Pai, McGill University

Conventional health facility based HIV testing is plagued with poor rates of testing and has been around for the past 15+ years. Further, about 40-60% of individuals tested in facilities are lost to follow up.

17 Dec 2013

Two existing drugs show promise as potential treatments for cervical cancer

Two existing drugs - one the active ingredient in an anti-fungal medication and the other now used to control iron levels in the blood - both show promise as potential treatments for cervical cancer, according to newly published research by scientists at Rutgers New Jersey Medical School.

17 Dec 2013

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

The National Institute of Allergy and Infectious Diseases has awarded two seven-year grants to Brigham and Women's Hospital to fund the AIDS Clinical Trial Group Network.

16 Dec 2013

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

A Massachusetts General Hospital research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men. In the Dec. 1 issue of the Journal of Infectious Diseases the investigators report finding that HIV-infected women had a greater prevalence of the type of coronary artery plaque most vulnerable to rupture than did uninfected women.

14 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load.

11 Dec 2013

Mylan Pharmaceuticals introduces Cabergoline Tablets USP, 0.5 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

5 Dec 2013

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Antiretroviral therapy for the treatment of HIV infection has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030, according to a new study published online in The Journal of Infectious Diseases. The analysis suggests these dramatic benefits could be even greater if more aggressive HIV testing and treatment strategies are implemented.

4 Dec 2013

Older HIV-positive men at higher risk of HPV that causes anal cancer

Human papillomavirus, or HPV, which can cause cervical cancer in women, is also known to cause anal cancer in both women and men. Now, a study led by researchers at the UCLA School of Nursing has found that older HIV-positive men who have sex with men are at higher risk of becoming infected with the HPVs that most often cause anal cancer.

4 Dec 2013

AHF commends donors for rallying to pledge financial support for Global Fund

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, today heartily praised donor countries for rallying to pledge financial support for the Global Fund to Fight AIDS, TB, and Malaria.

4 Dec 2013

EU pledges over $500 million to fight AIDS, TB and malaria

The European Union today announced at the Global Fund's Replenishment Conference in Washington, DC, new support of over US $500 million to fight AIDS, tuberculosis and malaria for the 2014-2016 period. The conference takes place just one day after World AIDS Day.

3 Dec 2013

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

World AIDS Day: (RED) invites the world to join in fight against AIDS

World AIDS Day marks a time to celebrate how far we've come in the fight to end AIDS, as well as a time to shine a global spotlight on the monumental, historical opportunity now upon us to deliver the world's first AIDS Free Generation in over 30 years.

30 Nov 2013

New methods reduce mother-to-child transmission of HIV from 23.9% to 2.4% in Gipuzkoa

Miren Apilánez, researcher in the Department of Paediatrics of the UPV/EHU-University of the Basque Country, has studied the evolution that took place between 1984 and 2011 in paediatric HIV infection in Gipuzkoa. The development of methods to diagnose the disease coupled with increasingly more effective treatments have made it possible to reduce mother-to-child transmission (vertical transmission) from 23.9% to 2.4%, thus virtually eradicating infection in children.

30 Nov 2013

Maintaining antiretroviral adherence: An ongoing challenge for women with HIV

To mark World AIDS Day (December 1, 2013), Women for Positive Action - a global, multidisciplinary group of experts committed to addressing the specific concerns of women living with HIV - has released a commentary highlighting the challenges faced by women in maintaining adherence to their antiretroviral treatment.

29 Nov 2013

Government of Canada awards $8.76M in funding to develop cure for HIV

In the push for a cure for HIV, the Government of Canada has announced $8.76 million in funding to Université de Montréal and Institut de recherches cliniques de Montréal Professor éric A. Cohen, who will lead an unrivaled group of Canadian investigators and international collaborators with a strong track record of interactive research.

29 Nov 2013

Antiretroviral News and Research

Study: High levels of depressive symptoms may be associated with delayed ART initiation

Mylan obtains exclusive rights from Pfizer to develop, commercialize novel LAMA compound

Mylan enters into agreement to resolve patent litigation related to Bexarotene Capsules

HIV self-test screening strategy: an interview with Dr. Nitika Pant Pai, McGill University

Two existing drugs show promise as potential treatments for cervical cancer

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Detectable blood viral load increases prevalence of heart disease

Mylan Pharmaceuticals introduces Cabergoline Tablets USP, 0.5 mg

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Older HIV-positive men at higher risk of HPV that causes anal cancer

AHF commends donors for rallying to pledge financial support for Global Fund

EU pledges over $500 million to fight AIDS, TB and malaria

Researchers offer promise of strategy for curing HIV infection

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

World AIDS Day: (RED) invites the world to join in fight against AIDS

New methods reduce mother-to-child transmission of HIV from 23.9% to 2.4% in Gipuzkoa

Maintaining antiretroviral adherence: An ongoing challenge for women with HIV

Government of Canada awards $8.76M in funding to develop cure for HIV

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News